Sector News

Shire considers takeover of Swiss biotech group Actelion -Sunday Times

June 8, 2015
Life sciences
(Reuters) – Pharmaceutical company Shire is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd Europe’s biggest biotech firm, Britain’s Sunday Times newspaper reported, citing unnamed sources.
 
An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources.
 
Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock’s Friday closing price of 132 francs.
 
Asked by Reuters for comment, a spokeswoman for Shire said the company did not comment on speculation. An Actelion spokesman said the company did not comment on market rumours.
 
Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts’ estimates.
 
At the time, the company’s chief executive told Reuters it had not received any outside interest to buy the company.
 
In April, Shire reported a better-than-expected 20 percent rise in first-quarter earnings, helped by the launch of the first drug to treat binge eating disorder.
 
($1 = 0.6549 pounds) (Reporting by William James; additional reporting by Joshua Franklin in Zurich; editing by Jane Merriman and Jason Neely)

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend